Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million ...

Hims & Hers Health, Inc. HIMS has seen a surge in retail investor interest, which positions it as one of the most ...

Hims & Hers, which markets compounded versions of semaglutide through its telehealth platform, released clinical data shortly after Novo’s statement. The data showed that users of its compounded GLP-1 ...

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and safety concerns.

Recently, Hims & Hers stock has rallied by over 20.3% over the past week alone, a reaction that came after news broke out stating that Hims & Hers had been added to the S&P 600 small-cap index.

Hims & Hers' stock (HIMS) sank 34.6% Monday, its largest one-day loss since the company went public in September 2019. The losses surpassed the stock's previous record selloff of 25.8% on Feb. 21 ...

In May, just before Hims & Hers announced it would give its customers low-cost GLP-1 injections for as little as $199 per month, the stock was trading at around $14. Last week, it closed at more ...